ID   PA216_HUMAN             Reviewed;         162 AA.
AC   P53816; B2R7Q4; B7XAK5; Q3SYI3; Q9HDD1;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   31-JAN-2002, sequence version 2.
DT   12-APR-2017, entry version 142.
DE   RecName: Full=HRAS-like suppressor 3 {ECO:0000303|PubMed:17374643};
DE            Short=HRSL3 {ECO:0000303|PubMed:17374643};
DE            EC=3.1.1.32 {ECO:0000269|PubMed:19047760, ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014, ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616};
DE            EC=3.1.1.4 {ECO:0000269|PubMed:19047760, ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014, ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616};
DE   AltName: Full=Adipose-specific phospholipase A2 {ECO:0000250|UniProtKB:Q8R3U1};
DE            Short=AdPLA {ECO:0000250|UniProtKB:Q8R3U1};
DE   AltName: Full=Group XVI phospholipase A1/A2 {ECO:0000312|HGNC:HGNC:17825};
DE   AltName: Full=H-rev 107 protein homolog {ECO:0000303|PubMed:9771974};
DE            Short=H-REV107 {ECO:0000303|PubMed:9771974};
DE            Short=HREV107-1 {ECO:0000303|PubMed:9771974};
DE   AltName: Full=HRAS-like suppressor 1;
DE   AltName: Full=HREV107-3;
DE   AltName: Full=Renal carcinoma antigen NY-REN-65 {ECO:0000303|PubMed:10508479};
GN   Name=PLA2G16 {ECO:0000312|HGNC:HGNC:17825};
GN   Synonyms=HRASLS3 {ECO:0000303|PubMed:22605381},
GN   HREV107 {ECO:0000303|PubMed:9771974};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9771974; DOI=10.1038/sj.onc.1202060;
RA   Husmann K., Sers C., Fietze E., Mincheva A., Lichter P., Schafer R.;
RT   "Transcriptional and translational downregulation of H-REV107, a class
RT   II tumour suppressor gene located on human chromosome 11q11-12.";
RL   Oncogene 17:1305-1312(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Kato S.;
RT   "Human cDNA encoding H-REV107 protein homolog.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=11526504; DOI=10.1038/sj.onc.1204658;
RA   Siegrist S., Feral C., Chami M., Solhonne B., Mattei M.G.,
RA   Rajpert-De Meyts E., Guellaen G., Bulle F.;
RT   "hH-Rev107, a class II tumor suppressor gene, is expressed by post-
RT   meiotic testicular germ cells and CIS cells but not by human
RT   testicular germ cell tumors.";
RL   Oncogene 20:5155-5163(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, CATALYTIC
RP   ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Testis;
RX   PubMed=19615464; DOI=10.1016/j.bbalip.2009.07.001;
RA   Uyama T., Jin X.H., Tsuboi K., Tonai T., Ueda N.;
RT   "Characterization of the human tumor suppressors TIG3 and HRASLS2 as
RT   phospholipid-metabolizing enzymes.";
RL   Biochim. Biophys. Acta 1791:1114-1124(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [9]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11973642; DOI=10.1038/sj.onc.1205377;
RA   Sers C., Husmann K., Nazarenko I., Reich S., Wiechen K.,
RA   Zhumabayeva B., Adhikari P., Schroder K., Gontarewicz A., Schafer R.;
RT   "The class II tumour suppressor gene H-REV107-1 is a target of
RT   interferon-regulatory factor-1 and is involved in IFNgamma-induced
RT   cell death in human ovarian carcinoma cells.";
RL   Oncogene 21:2829-2839(2002).
RN   [10]
RP   FUNCTION, INTERACTION WITH PPP2R1A, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF HIS-23 AND CYS-113.
RX   PubMed=17374643; DOI=10.1242/jcs.000018;
RA   Nazarenko I., Schafer R., Sers C.;
RT   "Mechanisms of the HRSL3 tumor suppressor function in ovarian
RT   carcinoma cells.";
RL   J. Cell Sci. 120:1393-1404(2007).
RN   [11]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=19047760; DOI=10.1194/jlr.M800453-JLR200;
RA   Uyama T., Morishita J., Jin X.H., Okamoto Y., Tsuboi K., Ueda N.;
RT   "The tumor suppressor gene H-Rev107 functions as a novel Ca2+-
RT   independent cytosolic phospholipase A1/2 of the thiol hydrolase
RT   type.";
RL   J. Lipid Res. 50:685-693(2009).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=19136964; DOI=10.1038/nm.1904;
RA   Jaworski K., Ahmadian M., Duncan R.E., Sarkadi-Nagy E., Varady K.A.,
RA   Hellerstein M.K., Lee H.Y., Samuel V.T., Shulman G.I., Kim K.H.,
RA   de Val S., Kang C., Sul H.S.;
RT   "AdPLA ablation increases lipolysis and prevents obesity induced by
RT   high-fat feeding or leptin deficiency.";
RL   Nat. Med. 15:159-168(2009).
RN   [13]
RP   FUNCTION (MICROBIAL INFECTION), AND MUTAGENESIS OF CYS-113.
RX   PubMed=28077878; DOI=10.1038/nature21032;
RA   Staring J., von Castelmur E., Blomen V.A., van den Hengel L.G.,
RA   Brockmann M., Baggen J., Thibaut H.J., Nieuwenhuis J., Janssen H.,
RA   van Kuppeveld F.J., Perrakis A., Carette J.E., Brummelkamp T.R.;
RT   "PLA2G16 represents a switch between entry and clearance of
RT   Picornaviridae.";
RL   Nature 541:412-416(2017).
RN   [14]
RP   STRUCTURE BY NMR OF 1-125, AND ACTIVE SITE.
RX   PubMed=20837014; DOI=10.1016/j.febslet.2010.09.015;
RA   Ren X., Lin J., Jin C., Xia B.;
RT   "Solution structure of the N-terminal catalytic domain of human H-
RT   REV107 -- a novel circular permutated NlpC/P60 domain.";
RL   FEBS Lett. 584:4222-4226(2010).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 1-132, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, AND SUBCELLULAR LOCATION.
RX   PubMed=22605381; DOI=10.1074/jbc.M112.361550;
RA   Golczak M., Kiser P.D., Sears A.E., Lodowski D.T., Blaner W.S.,
RA   Palczewski K.;
RT   "Structural basis for the acyltransferase activity of lecithin:retinol
RT   acyltransferase-like proteins.";
RL   J. Biol. Chem. 287:23790-23807(2012).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 1-134, CATALYTIC ACTIVITY,
RP   AND ACTIVE SITE.
RX   PubMed=22923616; DOI=10.1074/jbc.M112.398859;
RA   Pang X.Y., Cao J., Addington L., Lovell S., Battaile K.P., Zhang N.,
RA   Rao J.L., Dennis E.A., Moise A.R.;
RT   "Structure/Function relationships of adipose phospholipase A2
RT   containing a cys-his-his catalytic triad.";
RL   J. Biol. Chem. 287:35260-35274(2012).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 2-38 AND 59-129, AND
RP   MUTAGENESIS OF 39-PRO--LYS-57.
RX   PubMed=25383759; DOI=10.1038/nchembio.1687;
RA   Golczak M., Sears A.E., Kiser P.D., Palczewski K.;
RT   "LRAT-specific domain facilitates vitamin A metabolism by domain
RT   swapping in HRASLS3.";
RL   Nat. Chem. Biol. 11:26-32(2015).
CC   -!- FUNCTION: Lipid-modifying enzyme that acts as major regulator of
CC       adipocyte lipolysis by catalyzing the release of fatty acids from
CC       phospholipids in adipose tissue (PubMed:19615464, PubMed:19047760,
CC       PubMed:20837014, PubMed:22605381, PubMed:22923616). Shows
CC       phospholipase A1 and A2 activity, catalyzing the calcium-
CC       independent hydrolysis of acyl groups in various
CC       phosphatidylcholines (PC) and phosphatidylethanolamine (PE)
CC       (PubMed:19615464, PubMed:19047760, PubMed:20837014,
CC       PubMed:22605381, PubMed:22923616). For most substrates,
CC       phospholipase A1 activity is much higher than phospholipase A2
CC       activity (PubMed:19047760). Phospholipase activity causes
CC       decreased intracellular levels of ether-type lipids, affecting
CC       peroxisome metabolism (By similarity). May also have
CC       acyltransferase activity: catalyzes both N-acylation of
CC       phosphatidylethanolamine to form N-acyl-phosphatidylethanolamine
CC       and O-acylation of lyso-phosphatidylcholines to form
CC       phosphatidylcholines (PubMed:22605381, PubMed:25383759). The
CC       relevance of acyltransferase activity in vivo is however unclear
CC       and would require additional evidences (PubMed:22605381,
CC       PubMed:25383759). Also has weak lysophospholipase activity (By
CC       similarity). {ECO:0000250|UniProtKB:Q8R3U1,
CC       ECO:0000269|PubMed:17374643, ECO:0000269|PubMed:19047760,
CC       ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014,
CC       ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616,
CC       ECO:0000269|PubMed:25383759}.
CC   -!- FUNCTION: (Microbial infection) Acts as a host factor for
CC       picornaviruses: required during early infection to promote viral
CC       genome release into the cytoplasm (PubMed:28077878). May act as a
CC       cellular sensor of membrane damage at sites of virus entry, which
CC       relocalizes to sites of membrane rupture upon virus unfection
CC       (PubMed:28077878). Facilitates safe passage of the RNA away from
CC       LGALS8, enabling viral genome translation by host ribosome
CC       (PubMed:28077878). May also be involved in initiating pore
CC       formation, increasing pore size or in maintaining pores for genome
CC       delivery (PubMed:28077878). The lipid-modifying enzyme activity is
CC       required for this process (PubMed:28077878).
CC       {ECO:0000269|PubMed:28077878}.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
CC       acylglycerophosphocholine + a carboxylate.
CC       {ECO:0000269|PubMed:19047760, ECO:0000269|PubMed:19615464,
CC       ECO:0000269|PubMed:20837014, ECO:0000269|PubMed:22605381,
CC       ECO:0000269|PubMed:22923616}.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 2-
CC       acylglycerophosphocholine + a carboxylate.
CC       {ECO:0000269|PubMed:19047760, ECO:0000269|PubMed:19615464,
CC       ECO:0000269|PubMed:20837014, ECO:0000269|PubMed:22605381,
CC       ECO:0000269|PubMed:22923616}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=300 uM for dipalmitoyl-PC {ECO:0000269|PubMed:19615464};
CC         Vmax=2.57 umol/min/mg enzyme with dipalmitoyl-PC as substrate
CC         {ECO:0000269|PubMed:19615464};
CC         Vmax=267 nmol/min/mg enzyme with dipalmitoyl-PE as substrate
CC         {ECO:0000269|PubMed:19615464};
CC       pH dependence:
CC         Optimum pH is 9. {ECO:0000269|PubMed:19615464};
CC   -!- SUBUNIT: Interacts with PPP2R1A; this interaction might decrease
CC       PP2A activity. {ECO:0000269|PubMed:17374643}.
CC   -!- INTERACTION:
CC       P30153:PPP2R1A; NbExp=7; IntAct=EBI-746318, EBI-302388;
CC       Q9UMX0:UBQLN1; NbExp=6; IntAct=EBI-746318, EBI-741480;
CC       Q9UMX0-2:UBQLN1; NbExp=3; IntAct=EBI-746318, EBI-10173939;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305|PubMed:22605381};
CC       Single-pass membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:17374643}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:Q8R3U1}. Peroxisome membrane
CC       {ECO:0000250|UniProtKB:Q8R3U1}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. low expression, if any, in
CC       hematopoietic cells and thymus. In testis, confined to round
CC       spermatids. Expressed in normal ovarian epithelial cells. Down-
CC       regulated in some ovarian carcinomas and testicular germ cell
CC       tumors. Highly expressed in white adipose tissue
CC       (PubMed:19136964). {ECO:0000269|PubMed:11526504,
CC       ECO:0000269|PubMed:11973642, ECO:0000269|PubMed:19136964,
CC       ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:9771974}.
CC   -!- INDUCTION: By IFNG and IRF1. {ECO:0000269|PubMed:11973642}.
CC   -!- SIMILARITY: Belongs to the H-rev107 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X92814; CAA63423.1; -; mRNA.
DR   EMBL; AB030814; BAB08108.1; -; mRNA.
DR   EMBL; AF317086; AAL26892.1; -; mRNA.
DR   EMBL; AB439591; BAH08749.1; -; mRNA.
DR   EMBL; AK313075; BAG35901.1; -; mRNA.
DR   EMBL; CH471076; EAW74158.1; -; Genomic_DNA.
DR   EMBL; BC001387; AAH01387.1; -; mRNA.
DR   EMBL; BC103807; AAI03808.1; -; mRNA.
DR   CCDS; CCDS8047.1; -.
DR   RefSeq; NP_001121675.1; NM_001128203.1.
DR   RefSeq; NP_009000.2; NM_007069.3.
DR   RefSeq; XP_006718489.1; XM_006718426.1.
DR   UniGene; Hs.502775; -.
DR   PDB; 2KYT; NMR; -; A=1-125.
DR   PDB; 4DOT; X-ray; 1.96 A; A=1-132.
DR   PDB; 4FA0; X-ray; 2.65 A; A=1-134.
DR   PDB; 4Q95; X-ray; 2.20 A; A/B=2-38, A/B=59-129.
DR   PDBsum; 2KYT; -.
DR   PDBsum; 4DOT; -.
DR   PDBsum; 4FA0; -.
DR   PDBsum; 4Q95; -.
DR   ProteinModelPortal; P53816; -.
DR   SMR; P53816; -.
DR   BioGrid; 116317; 3.
DR   IntAct; P53816; 4.
DR   MINT; MINT-1461468; -.
DR   STRING; 9606.ENSP00000320337; -.
DR   SwissLipids; SLP:000001077; -.
DR   iPTMnet; P53816; -.
DR   PhosphoSitePlus; P53816; -.
DR   BioMuta; PLA2G16; -.
DR   DMDM; 20141767; -.
DR   EPD; P53816; -.
DR   MaxQB; P53816; -.
DR   PaxDb; P53816; -.
DR   PeptideAtlas; P53816; -.
DR   PRIDE; P53816; -.
DR   DNASU; 11145; -.
DR   Ensembl; ENST00000323646; ENSP00000320337; ENSG00000176485.
DR   Ensembl; ENST00000415826; ENSP00000389124; ENSG00000176485.
DR   GeneID; 11145; -.
DR   KEGG; hsa:11145; -.
DR   UCSC; uc001nxh.4; human.
DR   CTD; 11145; -.
DR   DisGeNET; 11145; -.
DR   GeneCards; PLA2G16; -.
DR   HGNC; HGNC:17825; PLA2G16.
DR   HPA; HPA058997; -.
DR   MIM; 613867; gene.
DR   neXtProt; NX_P53816; -.
DR   OpenTargets; ENSG00000176485; -.
DR   PharmGKB; PA164724584; -.
DR   eggNOG; ENOG410IW0Y; Eukaryota.
DR   eggNOG; ENOG4111TDD; LUCA.
DR   GeneTree; ENSGT00390000013327; -.
DR   HOGENOM; HOG000293227; -.
DR   InParanoid; P53816; -.
DR   KO; K16817; -.
DR   OMA; HVNNKHD; -.
DR   OrthoDB; EOG091G08MK; -.
DR   PhylomeDB; P53816; -.
DR   TreeFam; TF330836; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   SIGNOR; P53816; -.
DR   ChiTaRS; PLA2G16; human.
DR   GeneWiki; HRASLS3; -.
DR   GenomeRNAi; 11145; -.
DR   PRO; PR:P53816; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000176485; -.
DR   CleanEx; HS_PLA2G16; -.
DR   ExpressionAtlas; P53816; baseline and differential.
DR   Genevisible; P53816; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005778; C:peroxisomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005777; C:peroxisome; ISS:UniProtKB.
DR   GO; GO:0052740; F:1-acyl-2-lysophosphatidylserine acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008970; F:phosphatidylcholine 1-acylhydrolase activity; IDA:UniProtKB.
DR   GO; GO:0052739; F:phosphatidylserine 1-acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0016746; F:transferase activity, transferring acyl groups; TAS:Reactome.
DR   GO; GO:0046485; P:ether lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0007031; P:peroxisome organization; ISS:UniProtKB.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036149; P:phosphatidylinositol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036150; P:phosphatidylserine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0008654; P:phospholipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006644; P:phospholipid metabolic process; IDA:UniProtKB.
DR   GO; GO:1904177; P:regulation of adipose tissue development; ISS:UniProtKB.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISS:UniProtKB.
DR   InterPro; IPR007053; LRAT-like_dom.
DR   Pfam; PF04970; LRAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Membrane; Peroxisome;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1    162       HRAS-like suppressor 3.
FT                                /FTId=PRO_0000152484.
FT   TOPO_DOM      1    132       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    133    155       Helical. {ECO:0000255}.
FT   TOPO_DOM    156    162       Lumenal. {ECO:0000255}.
FT   ACT_SITE     23     23       {ECO:0000269|PubMed:20837014,
FT                                ECO:0000269|PubMed:22605381,
FT                                ECO:0000269|PubMed:22923616}.
FT   ACT_SITE     35     35       {ECO:0000269|PubMed:20837014,
FT                                ECO:0000269|PubMed:22605381,
FT                                ECO:0000269|PubMed:22923616}.
FT   ACT_SITE    113    113       Acyl-thioester intermediate.
FT                                {ECO:0000269|PubMed:20837014,
FT                                ECO:0000269|PubMed:22605381,
FT                                ECO:0000269|PubMed:22923616}.
FT   MUTAGEN      23     23       H->A: No effect on PPP2R1A-binding.
FT                                {ECO:0000269|PubMed:17374643}.
FT   MUTAGEN      39     57       PSEVAGAGAASVMSALTDK->DILLALTDDMGRTQKVVSNK
FT                                RLILGVIVKV: Induces a major structural
FT                                rearrangement accompanied by domain-
FT                                swapping dimerization and changes in
FT                                substrate-specificity.
FT                                {ECO:0000269|PubMed:25383759}.
FT   MUTAGEN     113    113       C->S: No effect on PPP2R1A-binding.
FT                                Impaired ability to act as a host factor
FT                                for picornaviruses.
FT                                {ECO:0000269|PubMed:17374643,
FT                                ECO:0000269|PubMed:28077878}.
FT   CONFLICT     90     90       S -> T (in Ref. 1; CAA63423 and 4;
FT                                BAH08749). {ECO:0000305}.
FT   STRAND       13     18       {ECO:0000244|PDB:4DOT}.
FT   STRAND       21     29       {ECO:0000244|PDB:4DOT}.
FT   STRAND       32     37       {ECO:0000244|PDB:4DOT}.
FT   STRAND       41     43       {ECO:0000244|PDB:2KYT}.
FT   STRAND       45     48       {ECO:0000244|PDB:2KYT}.
FT   HELIX        49     52       {ECO:0000244|PDB:2KYT}.
FT   STRAND       59     64       {ECO:0000244|PDB:4DOT}.
FT   HELIX        65     69       {ECO:0000244|PDB:4DOT}.
FT   STRAND       72     76       {ECO:0000244|PDB:4DOT}.
FT   HELIX        79     82       {ECO:0000244|PDB:4DOT}.
FT   HELIX        89     98       {ECO:0000244|PDB:4DOT}.
FT   TURN         99    101       {ECO:0000244|PDB:4DOT}.
FT   STRAND      103    109       {ECO:0000244|PDB:4Q95}.
FT   HELIX       110    122       {ECO:0000244|PDB:4DOT}.
SQ   SEQUENCE   162 AA;  17937 MW;  3565BFC756A6DA3C CRC64;
     MRAPIPEPKP GDLIEIFRPF YRHWAIYVGD GYVVHLAPPS EVAGAGAASV MSALTDKAIV
     KKELLYDVAG SDKYQVNNKH DDKYSPLPCS KIIQRAEELV GQEVLYKLTS ENCEHFVNEL
     RYGVARSDQV RDVIIAASVA GMGLAAMSLI GVMFSRNKRQ KQ
//
